One of the first people to introduce the metabolic syndrome -or trisyndrome mé tabolique -in the scientific literature was Camus in 1966 [1]. However, this entity did not receive much interest until Reaven in 1988 introduced syndrome X, characterised by hypertension, impairment in glucose and lipid metabolism and insulin resistance [2]. The metabolic syndrome -also called the insulin resistance syndrome -is a multifaceted syndrome characterised by five major abnormalities: obesity, hypertension, insulin resistance, glucose intolerance (impaired glucose tolerance/non-insulin-dependent diabetes mellitus (NIDDM)), and dyslipidaemia (hypertriglyceridaemia and low HDL-cholesterol). In addition, a number of other abnormalities such as microalbuminuria, hyperuricaemia, hyperfibrinogenaemia and increased levels of plasminogen activator inhibitor I and low concentrations of tissue plasminogen activator are often associated with the syndrome. The clinical importance of the metabolic syndrome is mainly due to the clustering of simultaneously occurring atherosclerotic risk factors in the same individual [2][3][4][5][6][7][8][9].The aetiology of the metabolic syndrome is poorly understood; both genetic and environmental factors are involved [2][3][4][5][6][7][8][9]. Possible common denominators for the various components of the syndrome are not known, although hyperinsulinaemia/insulin resistance are important characteristics in most of the abnormalities.The prevalence rate of the metabolic syndrome varies depending on the population studied and the definition applied. As in any syndrome, not all features are present in the same individual. The estimated prevalence rate of the metabolic syndrome in western countries is 25-35 % [2-9]. On the other hand, both Ferrannini and Rupp [8, 9] have reported that only about one-third of an adult study population was free of all major characteristics of the metabolic syndrome. Since the prevalence of hypertension, insulin resistance and glucose intolerance usually increase with increasing age, the prevalence of the metabolic syndrome will probably also rise in the aging western society.A number of pharmacological therapies can be used for the treatment of the metabolic syndrome; but the results of most of the available therapies are often unsatisfactory, although some trials with metformin and thiazolidinediones have been encouraging [6, 10, 11].Low levels of physical activity are related to most components of the metabolic syndrome [12][13][14][15][16]. Consequently this offers a unique opportunity to employ increased physical activity in the prevention and treatment of the metabolic syndrome and its components. This review will focus on the role of physical activity and exercise in the prevention and treatment of the metabolic syndrome.
ObesityThe prevalence of obesity (body mass index (BMI) > 27 kg/m 2 ) is currently 25-35 % in most western societies, and is increasing [17]. If the prevalence continues to increase, as during the past decades, by the year 2230, 100 % of the adult Uni...